Why Are Shares of Pfizer Up Today? - Pfizer ( NYSE:PFE )
Shares of Pfizer, Inc. ( NASDAQ:PFE ) are trading higher after a study found that the company's new mRNA flu vaccine outperforms traditional shots against predominant strains. What To Know: A study published in the New England Journal of Medicine said that flu vaccine outperformed the ...
Texas AG Sues Sanofi And Bristol-Myers Over Alleged Failures To Warn About Risks Associated With Blood Thinner Drug - Pfizer ( NYSE:PFE ) , Bristol-Myers Squibb ( NYSE:BMY ) , Sanofi ( NASDAQ:SNY )
Texas Attorney General Ken Paxton escalated his campaign against major drugmakers this week, filing a new lawsuit accusing Sanofi SA ( NASDAQ:SNY ) and Bristol-Myers Squibb Co ( NYSE:BMY ) of concealing critical information about the effectiveness of their blood-thinning medication Plavix.
Alation Named as a Leader 5x in the Gartner® Magic Quadrant™ for Metadata Management Solutions
Alation Named as a Leader 5x in the Gartner® Magic Quadrantâ„¢ for Metadata Management Solutions ...
Alation Named as a Leader 5x in the Gartner® Magic Quadrant™ for Metadata Management Solutions
REDWOOD CITY, Calif., Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- Alation Inc., the data intelligence company, today announced it has been named a Leader in the Gartner® Magic Quadrant™ for Metadata Management Solutions for the fifth time.
Pfizer's New mRNA Flu Vaccine Outperforms Traditional Shot Against Predominant Strains - Pfizer ( NYSE:PFE )
A Phase 3 study funded by Pfizer Inc. ( NYSE:PFE ) suggests that a nucleoside-modified messenger RNA influenza vaccine could offer stronger protection than traditional flu shots, marking a potential shift in how seasonal influenza is prevented.
Eli Lilly hits $1 trillion market value, a first for a health-care company
The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and diabetes treatment Mounjaro.
Is Trending Stock Pfizer Inc. ( PFE ) a Buy Now?
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Inside the Recent Strength in Biotech ETFs
Biotech strength is back, with IBB, PBE, FBT, CANC and HELX climbing as cheaper valuations, rate-cut hopes, FDA approvals and strong deal activity fuel biotech gains.
This 7%-Yielding Dividend Stock Is About to Enter an Exciting New Phase
The drugmaker may not continue to lag the market for much longer.
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
XOMA Royalty Completes Acquisition of LAVA Therapeutics. Brings 2 partnered assets into XOMA Royalty's milestone and royalty portfolio.
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V. - XOMA Royalty ( NASDAQ:XOMA ) , LAVA Therapeutics ( NASDAQ:LVTX )
EMERYVILLE, Calif., Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- XOMA Royalty Corporation ( "XOMA Royalty" ) ( NASDAQ:XOMA ) today announced it has successfully completed its previously announced acquisition of all the outstanding common shares of LAVA Therapeutics N.V. ( "LAVA" ) ( NASDAQ:LVTX ) with a ...
PFE's New & Acquired Drugs Drive Non-COVID Comeback as LOE Test Looms
Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.
Goldman Sachs Just Delivered Bad News for U.S. Investors ... Sort Of. Here's What You Need to Know.
The investment bank's analysts simply recognize how much has changed in just the past few years, and what that means for the near future.
Will Librexia ACS Study Setback Dent BMY's Cardiovascular Portfolio?
BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.
VKTX Completes Enrollment in First Late-Stage Study on Obesity Drug
Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.
Is Pfizer's 6.9%-Yielding Dividend Still Safe?
The company's earnings fell by 21% last quarter.
Valneva Reports Nine-Month 2025 Financial Results and Provides Corporate Updates
Saint-Herblain ( France ) , November 20, 2025 - Valneva SE ( Nasdaq: VALN. Euronext Paris: VLA ) , a specialty vaccine company, today reported consolidated financial results for the first nine months of the year, ended September 30, 2025.
Ascentage Pharma to Participate in Three Upcoming Investor Conferences in December 2025 - Ascentage Pharma Group ( NASDAQ:AAPG )
ROCKVILLE, Md. and SUZHOU, China, Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- Ascentage Pharma Group International ( NASDAQ:AAPG, HKEX: 6855 ) ) ( "Ascentage Pharma" or the "Company" ) , a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and ...
Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery
Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery
Saudi Arabia To Buy Nearly 300 US Tanks In Defense Deal, Boosts Investment Commitment To $1 Trillion - Lockheed Martin ( NYSE:LMT ) , General Dynamics ( NYSE:GD )
Saudi Arabia has committed to purchasing hundreds of U.S.-made tanks, underlining an expansive defense and economic partnership with the United States. The White House revealed on Tuesday that the Trump administration has finalized a series of agreements with Riyadh, including the procurement of ...
Can AI Drive Peloton's Comeback?
The market is hopping with interesting news.
J&J Joins Pharma M&A Bandwagon, to Buy Cancer Biotech for $3.05B
J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.
Pfizer Trading Above 50-Day SMA: Is it a Good Time to Buy the Stock?
PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.
2 No-Brainer Healthcare Stocks to Buy Now
These two healthcare stocks scan as bargains right now.
Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?
Pfizer's weight management pipeline just got a boost.
Novo Nordisk's New Chair Aims To Reinforce Board As Foundation Tightens Control - Novo Nordisk ( NYSE:NVO )
Newly installed Chairperson Lars Rebien Sorensen signaled a rapid shift in governance and strategic direction at Novo Nordisk A/S ( NYSE:NVO ) , saying he intends to strengthen the board's pharmaceutical and over-the-counter expertise while easing concerns about the sweeping power now held by ...
2 Giant Healthcare Stocks to Buy Hand Over Fist in November
Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive healthcare investments in November.
SeaStar Medical Announces Appointment of Michael Messinger as CFO
DENVER, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- SeaStar Medical Holding Corporation ( Nasdaq: ICU ) , a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a ...
SeaStar Medical Announces Appointment of Michael Messinger as CFO - SeaStar Medical Holding ( NASDAQ:ICU )
DENVER, Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- SeaStar Medical Holding Corporation ( NASDAQ:ICU ) , a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life, announced today that Michael Messinger, a ...
MRK to Buy Cidara for $9.2B: Focus on Buyout Spree Heading Into 2026
Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.
MRK Up Nearly 10% in a Month: Should You Buy, Sell or Hold the Stock?
Merck rebounds on pipeline wins and a $9.2B Cidara deal, but mixed trends and Keytruda risks keep investors weighing next moves.
Fortrea Appoints Agnieszka Gallagher as General Counsel - Fortrea Holdings ( NASDAQ:FTRE )
DURHAM, N.C., Nov. 17, 2025 ( GLOBE NEWSWIRE ) -- Fortrea ( NASDAQ:FTRE ) ( the "Company" ) , a leading global contract research organization ( CRO ) , today announced the appointment of Agnieszka ( Aggie ) M. Gallagher as general counsel.
This Sector Is Suddenly Crushing the Broader Market. Should You Invest $1,000?
Healthcare stocks have far outperformed the broader market over the past month.
Down 55%, Should You Buy the Dip on Pfizer?
Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds. it will survive.
Michael Burry Bets Against Nvidia and Palantir. But It's Not What You Think.
Burry bought $1.1 billion of put options in these stocks.
Is Pfizer Stock a Buy After This $10 Billion Acquisition?
The company has been on an acquisition spree for years, and this one may be the most important yet.
Deal Dispatch: WBD, Bill.com, C3 AI Auctions Shake Market - C3.ai ( NYSE:AI ) , BILL Holdings ( NYSE:BILL )
An auction is underway for Bill.com ( NYSE:BILL ) . The business-payments firm, according to Bloomberg, tapped a financial adviser to solicit bids. The sale follows activist pressure from Starboard Value, a firm known for buying up stakes in public companies to get deal processes going.
Iterum Therapeutics ( ITRM ) Earnings Transcript
Image source: The Motley Fool.Friday, November 14, 2025 at 8:30 a.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Ozempic Maker Novo Nordisk Faces Board Shakeup - Novo Nordisk ( NYSE:NVO )
On Friday, Novo Nordisk A/S' ( NYSE:NVO ) board director Mikael Dolsten said he will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025.
Can Lilly's Next-Gen Obesity Drugs Help Sustain Its Market Dominance?
Eli Lilly's next-gen obesity drugs, led by oral orforglipron and triple-acting retatrutide, aim to reshape the fast-growing weight-loss market.
Pharma ETFs in Spotlight Following Robust Q3 Earnings Results
Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields - Metsera ( NASDAQ:MTSR ) , Pfizer ( NYSE:PFE )
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high dividend payout.
Why Is Everyone Talking About Novo Nordisk Stock?
There is hardly a dull moment for the drugmaker these days.
Novo Nordisk A/S: Candidate for the Board of Directors will not seek election
Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November ...
Calidi Biotherapeutics Reports Third Quarter 2025 Financial Results and Recent Operational Highlights
SAN DIEGO, Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Calidi Biotherapeutics Inc. ( NYSE American: CLDI ) ( "Calidi" ) , a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its ...
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
Dyadic ( DYAI ) Q3 2025 Earnings Call Transcript
Image source: The Motley Fool.Wednesday, November 12, 2025 at 5 p.m. ETNeed a quote from a Motley Fool analyst? Email [email protected] reading ...
Why Is BioNTech Stock Falling Today? - Pfizer ( NYSE:PFE ) , BioNTech ( NASDAQ:BNTX )
Pfizer ( NYSE:PFE ) is reportedly offloading its remaining stake in Covid-19 vaccine partner BioNTech SE ( NASDAQ:BNTX ) . It seeks an overnight block trade of about 4.55 million American depositary receipts, priced between $108 and $111.70 apiece, according to a Bloomberg report.
Alation Honors 2025 Data Radicals Award Winners at revAlation
REDWOOD CITY, Calif., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Alation Inc., the data intelligence company, today announced the winners of the 2025 Data Radicals Awards, presented at revAlation London, the company's global conference series.
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update
WARMINSTER, Pa., Nov. 13, 2025 ( GLOBE NEWSWIRE ) -- Arbutus Biopharma Corporation ( Nasdaq: ABUS ) ( "Arbutus" or the "Company" ) , a clinical-stage biopharmaceutical company focused on infectious disease, today reported third quarter 2025 financial results and provided a corporate update.
